Impaired bone strength and bone microstructure in a novel early-onset osteoporotic rat model with a clinically relevant PLS3 mutation
Curation statements for this article:-
Curated by eLife
eLife assessment
The findings in this study are important as they establish a rat model of a classic form of early-onset osteoporosis and demonstrate that osteoporosis medications are effective in the model. The evidence supporting the authors' claims is compelling.
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
- Genetics and Genomics (eLife)
Abstract
Plastin 3 (PLS3), a protein involved in formation of filamentous actin (F-actin) bundles, is important in human bone health. Recent studies identify PLS3 as a novel bone regulator and PLS3 mutations can lead to a rare monogenic early-onset osteoporosis. However, the mechanism of PLS3 mutation leading to osteoporosis is unknown, and its effective treatment strategies have not been established. Here, we have constructed a novel rat model with clinically relevant hemizygous E10-16del mutation in PLS3 ( PLS3 E10-16del/0 ) that recapitulates the osteoporotic phenotypes with obviously thinner cortical thickness, significant decreases in yield load, maximum load, and breaking load of femora at 3, 6, 9 months old compared to wild-type rats. Histomorphometric analysis indicates a significantly lower mineral apposition rate in PLS3 E10-16del/0 rats. Treatment with alendronate (1.0 µg/kg/day) or teriparatide (40 µg/kg five times weekly) for 8 weeks significantly improves bone mass and bone microarchitecture, and bone strength is significantly increased after teriparatide treatment (p＜0.05). Thus, our results indicate that PLS3 plays an important role in the regulation of bone microstructure and bone strength, and we provide a novel animal model for the study of X-linked early-onset osteoporosis. Alendronate and teriparatide treatment could be a potential treatment for early-onset osteoporosis induced by PLS3 mutation.
Article activity feed
-
-
eLife assessment
The findings in this study are important as they establish a rat model of a classic form of early-onset osteoporosis and demonstrate that osteoporosis medications are effective in the model. The evidence supporting the authors' claims is compelling.
-
Reviewer #1 (Public Review):
The author constructed a novel rat model with a clinically relevant PLS3 hemizygous E10-16del mutation (PLS3E10-16del/0), which presents a classic form of early-onset osteoporosis, which recapitulate the osteoporotic phenotypes. Treatment with alendronate and teriparatide significantly improved bone mass and bone microarchitecture. Their results showed alendronate and teriparatide treatment could be a potential treatment for early-onset osteoporosis induced by PLS3 mutation.
This experiment is very interesting and has clinical relevance. The authors used common clinical drugs to treat osteoporosis caused by PLS3 mutation and achieved certain results. This result will give a way to the treatment of osteoporosis induced by PLS3 mutation.
-
Reviewer #2 (Public Review):
The mechanism for early-onset osteoporosis (EOOP) is not well understood. The authors performed PLS3 knockout and characterized its bone phenotype in a rat model. This provides a very useful tool for studying EOOP and the potential treatment for EOOP. The authors did a very nice job of characterizing the phenotype including the assessments of bone turnover markers, bone histomorphometric analyses, and bone biomechanical tests. The results from these assessments led to the conclusion that this PLS3 knockout rat model mimics the human EOOP. In addition, treatment with currently available drugs for osteoporosis is effective in this EOOP model. These results support further clinical investigation of anti-osteoporosis drugs for EOOP management.
-
